Megan Dulohery Scrodin, MD
Pulmonary Disease · Rochester, MNNPI 1649435884
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,611 of the $5,724 with a category attached, or 98.0%. Regeneron accounts for 66.0% of it on its own, with 2 other manufacturers making up the rest.
Across 3 payments — averaging $1907.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$4K
- Sanofi$2K
- Astrazeneca UK Limited$113
Across 16 payments — averaging $17,501 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$180K
- AstraZeneca$60K
- Sanofi US Services Inc.$40K
What the payments were for
- Consulting fees$5,61198%
- Food & beverage$1132%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $3,775 |
| Sanofi | 1 | $1,836 |
| Astrazeneca UK Limited | 1 | $113 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$3,775
How this compares
$5,724 in reported general payments places this provider in the 85th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 41 | $151,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $100,841 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $32,447 |
| Spiriva RespimatTiotropium Bromide | 48 | $28,055 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $26,627 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $26,479 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $17,166 |
| DuleraMometasone/Formoterol | 23 | $12,233 |
| Arnuity ElliptaFluticasone Furoate | 34 | $11,804 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,133 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,032 |
| Tudorza PressairAclidinium Bromide | 11 | $4,632 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $3,802 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,273 |
| Azithromycin | 109 | $2,555 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Rochester
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Jagdeep BijwadiaRochester$54K
- Teng MouaRochester$47K
- Timothy AksamitRochester$26K
- Michael KrowkaRochester$25K
- Kaiser LimRochester$18K
- Robert VassalloRochester$18K
- Eva Carmona PorqueraRochester$17K
- Tobias PeikertRochester$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.